{"id":"standard-of-care-antifungal-prophylaxis","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Standard of care antifungal prophylaxis drugs typically work by inhibiting the growth of fungi through various mechanisms, such as interfering with cell wall synthesis or inhibiting the production of essential nutrients. This can help prevent the spread of fungal infections in patients who are at high risk.","oneSentence":"This drug works by inhibiting the growth of fungi.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:17.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive fungal infections in patients undergoing chemotherapy or hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT06666322","phase":"PHASE2, PHASE3","title":"Platform Trial For Cryptococcal Meningitis","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-05-28","conditions":"Hiv, Cryptococcal Meningitis","enrollment":2000},{"nctId":"NCT03828773","phase":"NA","title":"PTX3-targeted Antifungal Prophylaxis","status":"RECRUITING","sponsor":"Bochud Pierre-Yves","startDate":"2019-02-11","conditions":"Candidiasis, Fungal Infection, Acute Myeloid Leukemia","enrollment":410},{"nctId":"NCT06774144","phase":"PHASE3","title":"Rezafungin Prophylaxis in Liver Transplant","status":"ENROLLING_BY_INVITATION","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2025-10-15","conditions":"Liver Transplant Infection, Fungal Infection","enrollment":385},{"nctId":"NCT06926569","phase":"NA","title":"Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2025-05-01","conditions":"HIV/AIDS-associated Talaromycosis","enrollment":116},{"nctId":"NCT05443854","phase":"PHASE3","title":"Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09","conditions":"Sepsis, Septic Shock, Hematologic Malignancy","enrollment":340},{"nctId":"NCT02583204","phase":"NA","title":"Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2015-10","conditions":"Breast Cancer, Nail Toxicity","enrollment":105},{"nctId":"NCT00672841","phase":"NA","title":"β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2008-06","conditions":"Invasive Candidiasis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluconazole, voriconazole, or no prophylaxis"],"phase":"phase_3","status":"active","brandName":"Standard of care antifungal prophylaxis","genericName":"Standard of care antifungal prophylaxis","companyName":"Fernanda P Silveira, MD, MS","companyId":"fernanda-p-silveira-md-ms","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug works by inhibiting the growth of fungi. Used for Prevention of invasive fungal infections in patients undergoing chemotherapy or hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}